Prostate cancer Posts - Page 2 of 78 on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Posted by on Jan 9, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness. Some background BRCA1 and BRCA2 gene mutations (abnormalities) can be found in...

Read More

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Posted by on Dec 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study assessed patient responses to focal thermo-ablative therapy (FTA) for oligo-recurrent prostate cancer (PCa) after pelvic radiotherapy. The data suggested that FTA therapy is a good option in these patients. Some background Oligometastatic PCa means that cancer has spread to only a few places (up to 5 metastases). It...

Read More

Comparing the effectiveness and safety of apalutamide with darolutamide for non-metastatic castration-resistant prostate cancer.

Comparing the effectiveness and safety of apalutamide with darolutamide for non-metastatic castration-resistant prostate cancer.

Posted by on Dec 19, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness and safety outcomes of androgen-deprivation therapy (ADT) with either apalutamide (Erleada) or darolutamide (Nubeqa) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). The data showed that apalutamide plus ADT was safe and more effective in improving...

Read More

Recommendations for enhancing sexual rehabilitation for survivors of prostate cancer.

Recommendations for enhancing sexual rehabilitation for survivors of prostate cancer.

Posted by on Dec 5, 2021 in Prostate cancer | 0 comments

In a nutshell This study highlights psychosocial recommendations for survivors of prostate cancer (PCa) and their partners during sexual rehabilitation. The authors concluded that biopsychosocial programs are beneficial for providing educational support and psychosocial counseling to patients with erectile dysfunction in addition to existing biomedical...

Read More

Evaluating the effectiveness of androgen receptor-targeted therapy plus radiotherapy in patients with metastatic castration resistant prostate cancer.

Evaluating the effectiveness of androgen receptor-targeted therapy plus radiotherapy in patients with metastatic castration resistant prostate cancer.

Posted by on Nov 28, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of radiotherapy (RT) plus androgen receptor-targeted therapy (ARTT) on oligo-progressive sites for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that RT on oligo-progressive sites was safe and effective in prolonging treatment with ARTT in...

Read More

Reviewing the changes in quality of life and lower urinary tract symptoms in patients with prostate cancer following prostate surgery

Reviewing the changes in quality of life and lower urinary tract symptoms in patients with prostate cancer following prostate surgery

Posted by on Nov 14, 2021 in Prostate cancer | 0 comments

In a nutshell This review explained the changes in lower urinary tract symptoms (LUTS) and quality of life (QoL) that occurred over time in patients with prostate cancer following radical prostatectomy (RP; removal of the prostate). The data showed that 6 to 12 months are required for LUTS improvement after RT. Some background Patients with prostate...

Read More

Comparing outcomes after robot‑assisted and laparoscopic prostate surgery for patients with localized prostate cancer with a large prostate volume.

Comparing outcomes after robot‑assisted and laparoscopic prostate surgery for patients with localized prostate cancer with a large prostate volume.

Posted by on Nov 14, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the surgical, functional, and oncological outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer (PCa) with a large prostate volume. The study found that RARP was associated with better surgical,...

Read More

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Posted by on Nov 7, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...

Read More

Evaluating the effectiveness and safety of apalutamide plus abiraterone and prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of apalutamide plus abiraterone and prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Nov 7, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of apalutamide (Erleada) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that apalutamide plus AAP combination significantly improved...

Read More

Evaluating the effectiveness and safety outcomes of second radiation therapy in patients with locally recurrent prostate cancer.

Evaluating the effectiveness and safety outcomes of second radiation therapy in patients with locally recurrent prostate cancer.

Posted by on Oct 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of re-irradiation for the treatment of patients with locally recurrent prostate cancer. The data showed that the use of re-irradiation in these patients was associated with good outcomes and low toxicity. Some background Radiotherapy (RT) is an effective treatment for localized...

Read More

Evaluating the effectiveness of extended robot-assisted prostate surgery and extended pelvic lymph node dissection in patients with very high-risk prostate cancer.

Evaluating the effectiveness of extended robot-assisted prostate surgery and extended pelvic lymph node dissection in patients with very high-risk prostate cancer.

Posted by on Oct 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the effectiveness of extended robotic-assisted laparoscopic prostatectomy (eRALP) with extended pelvic lymph node dissection (ePLND) without any other additional treatments for patients with very-high-risk localized prostate cancer (PCa). The study found that eRALP with ePLND alone was safe and effective...

Read More

Evaluating the long-term functional and oncological outcomes after open versus robot-assisted prostate surgery for localized prostate cancer.

Evaluating the long-term functional and oncological outcomes after open versus robot-assisted prostate surgery for localized prostate cancer.

Posted by on Oct 24, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the long-term functional and oncological outcomes of robotic-assisted laparoscopic radical prostatectomy (RALP) and open retropubic radical prostatectomy (RRP) for the treatment of patients with localized prostate cancer (PCa). This study found that RALP was associated with better oncological outcomes compared to...

Read More